Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
RARE
Stock Latest News
The Fly
Rezolute appoints Karnawat as Chief Commercial Officer
9d ago
CYTK
RARE
Premium
Ratings
Ultragenyx’s Strategic Progress with DTX401 Gene Therapy Drives Buy Rating Amid Promising Market Potential
9d ago
RARE
Premium
Ratings
Ultragenyx Pharmaceutical: Promising Developments and Strategic Advancements Support Buy Rating
10d ago
RARE
Premium
Company Announcements
Ultragenyx Begins FDA Application for DTX401 Gene Therapy
11d ago
8K
RARE
Premium
The Fly
Ultragenyx initiates rolling submission of BLA to U.S. FDA for DTX401
11d ago
RARE
Premium
Ratings
Ultragenyx Pharmaceutical’s Setrusumab: A Promising Buy with Potential for Significant Fracture Reduction in Osteogenesis Imperfecta
18d ago
RARE
Premium
The Fly
Ultragenyx price target lowered to $128 from $136 at Canaccord
21d ago
RARE
Premium
Ratings
Ultragenyx Pharmaceutical’s Promising Growth and Financial Outlook: Analyst Recommends Buy
22d ago
RARE
Premium
Company Announcements
Ultragenyx Earnings Call: Clinical Wins Amid Financial Challenges
22d ago
RARE
Premium
Ratings
Ultragenyx Pharmaceutical: Strong Q2 Results and Promising Future Justify Buy Rating
22d ago
RARE
Premium
Company Announcements
Ultragenyx Reports Growth Amidst Strategic Advancements
23d ago
RARE
Premium
The Fly
Ultragenyx reports Q2 EPS ($1.17), consensus ($1.32)
23d ago
RARE
Premium
The Fly
Ultragenyx backs FY25 revenue view $640M-$670M, consensus $649.53M
23d ago
RARE
Premium
Ratings
Ultragenyx Pharmaceutical’s Promising Outlook: Buy Rating Affirmed Amidst Aspire Study Progress
25d ago
RARE
Premium
Pre-Earnings
RARE Earnings this Week: How Will it Perform?
26d ago
RARE
Premium
Company Announcements
Ultragenyx Completes Enrollment for GTX-102 Phase 3 Study
28d ago
8K
RARE
Premium
The Fly
Ultragenyx completes enrollment of GTX-102 trial
28d ago
RARE
Premium
The Fly
Ultragenyx assumed with a Buy at H.C. Wainwright
1M ago
RARE
Premium
Ratings
Ultragenyx’s UX111 CRL Not a Major Setback; Focus Remains on Promising Programs with Outperform Rating Maintained
1M ago
RARE
Premium
Ratings
Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid Manageable FDA Setbacks and Promising Clinical Data
2M ago
RARE
Premium
The Fly
Ultragenyx participates in a conference call with JPMorgan
2M ago
RARE
Premium
The Fly
Ultragenyx price target lowered to $79 from $80 at BofA
2M ago
RARE
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.